Neel AcharyMumbai, October 2, 2025: Remedium Lifecare Ltd., a rapidly growing player in the pharmaceutical supply chain and specialty chemicals sector, has successfully concluded its 36th Annual General Meeting (AGM) and Board Meeting.
At the AGM, shareholders approved the adoption of the audited standalone and consolidated financial statements for FY25. They also approved the re-election of Mr. Mansoor Vahab as Non-executive Director, who retires by rotation.
The management also outlined forward-looking initiatives, including the expansion of global operations through its wholly owned subsidiary, Remlife Global PTE, which will strengthen international trade activities, and entry into the Contract Development and Manufacturing (CDMO) segment to collaborate with leading pharma players and create sustainable long-term value.
Separately, the Board of Directors approved several strategic proposals. These include a proposal to change the company’s name to SUPRA PHARMACHEM LIMITED or any other name as approved by the ROC subject to the approval of shareholders, Stock Exchanges, and other statutory/regulatory authorities as may be required. The Board has also approved an increase in the authorised share capital of the Company from ₹110 crores to ₹210 crores. The Board further approved raising up to ₹100 crores through equity shares, convertible instruments, rights issue, or other permissible securities, in one or more tranches, subject to regulatory approvals.
FY 2024–25 was a year of resilience and steady progress for the company despite industry-wide challenges. However, in Q1 FY 25-26 on a consolidated basis, the company reported Profit After Tax (PAT) of ₹464.88 lacs compared to net loss of ₹204.60 lacs in Mar-25. These results reflect disciplined financial management and a strong commitment to sustainable growth.
Commenting on these developments, Mr. Adarsh Munjal, Managing Director of Remedium Lifecare Ltd., said: “FY25-26 marks an important transition phase for us as we focus on global expansion and strengthen our service capabilities through CDMO opportunities. The Board’s decision to explore a new identity and raise fresh capital underlines our commitment to accelerate growth, enhance shareholder value, and position ourselves strongly in the evolving pharma landscape.”
Remedium Lifecare Ltd. is a fast-growing company engaged in the pharmaceutical supply chain and specialty chemicals segment. With a focus on innovation, operational excellence, and global expansion, the company is committed to delivering sustainable value to stakeholders while contributing to the healthcare ecosystem.
About Remedium Lifecare Ltd:
Founded in 1988, Remedium Lifecare Ltd. is a BSE-listed pharmaceutical company engaged in the trading and distribution of raw material as a supply chain management for the pharmaceutical industry with an emphasis on quality, compliance and global reach, the company continues to expand its presence while playing a pivotal role in India’s pharmaceutical ecosystem
